Wenzhong Guo

Wenzhong Guo has over 30 years of work experience in the biopharmaceutical industry and academia. Wenzhong began their career as an Instructor at Hubei University of Chinese Medicine, where they taught Clinical Immunology and Experimental Hematology and developed immunoassay kits for clinical diagnostics.

Wenzhong then worked as a Postdoctoral Fellow at MD Anderson Cancer Center, where they conducted research in cancer immunology. This was followed by a role as a Postdoctoral Researcher at the University of California, Irvine, where they constructed an antibody library and expressed disease-related antibodies.

Guo then joined National Jewish Health and the University of Colorado Immunology Department as a Research Associate, quickly progressing to the roles of Researcher and Senior Researcher. During this time, they focused on immunobiology research related to B cell and T cell tolerance in tumor immune tolerance and autoimmune diseases. Wenzhong gained extensive knowledge and experience in areas such as B and T cell biology, molecular immunology technology, and cell culture techniques.

In 2011, Guo joined Dophen Biomedicals of CSCP pharmaceutical group as a Senior Scientist, leading the development of antibody drugs and managing the CMC development for ADC drugs. Wenzhong also established high expression CHO cell lines and developed cell culture and purification processes.

Currently, Guo holds the position of Chief Technical Officer, Cell Therapy, at Sorrento Therapeutics, Inc. Wenzhong has held various roles within the company since joining in 2013, including VP of Cell Therapy and Senior Director of Cell Therapy. Wenzhong'sresponsibilities have included leading non-viral vector CAR-T technology and product development, viral vector production, cell line development, and PD and cGMP manufacturing.

Overall, Guo has a diverse background and expertise in cell therapy, antibody development, immunology, and molecular biology.

Wenzhong Guo earned a Bachelor's Degree in Cell Biology from Wuhan University in an unspecified year prior to 1990. Wenzhong then pursued further education and obtained a Doctor of Philosophy (Ph.D.) degree in Tumor Molecular Genetics and Tumor Immunology from Peking Union Medical College & Chinese Academy of Medical Sciences, starting in 1994 and completing it in 2000.